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Spinal cord injury (SCI) is one of the major disabilities dealt with in clinical rehabilitation settings and is multifactorial in that the
patients suﬀer from motor and sensory impairments as well as many other complications throughout their lifetimes. Many clinical
trials have been documented during the last two decades to restore damaged spinal cords. However, only a few pharmacological
therapies used in clinical settings which still have only limited eﬀects on the regeneration, recovery speed, or retraining of
the spinal cord. In this paper, we will introduce recent clinical trials, which performed pharmacological treatments and cell
transplantations for patients with SCI, and evaluate recent in vivo studies for the regeneration of injured spinal cord, including
stem-cell transplantation, application of neurotrophic factors and suppressor of inhibiting factors, development of biomaterial
scaﬀoldsanddeliverysystems,rehabilitation,andthecombinationsofthesetherapiestoevaluatewhatcanbeappropriatelyapplied
in the future to the patients with SCI.
1.Introduction
The incidence of traumatic SCI is about 10–30 new cases
per million among the population in Europe and 27–83
per million population in USA. Estimated prevalence is
approximately 225,000 to 288,000 cases in the United States
[1]. The major cause of traumatic SCI is motor vehicle
accidents (45%–47% of all traumatic SCI), sports-related,
accidents and falls [2].
Most of the currently used managements for SCI have
focused on either the rehabilitation of patients with para-
plegia or tetraplegia to maximize the remaining functions of
the upper and/or lower extremities, or the prevention and
management of complications after spinal cord injury, such
asneurogenicbladderandbowel,decubitusulcer,orthostatic
hypotension, deep vein thrombosis, and autonomic dysre-
ﬂexia. These management focuses have improved the quality
of life for patients with SCI, but fundamental treatment to
regenerate the damaged spinal cord tissues and neural cells
hasnotbeenstandardized,andnodrughasyettobeeﬀective
in improving the functional and clinical status.
Many studies have revealed some eﬀective strategies
for regenerating injured spinal cord through in vivo and
in vitro studies, but there are many steps to reach the
clinical application for the patients with SCI, due to the
lack of mechanism of treatment, safety for humans, and
potential adverse eﬀects. We reviewed recent clinical trials of
medications and stem cell transplantation for SCI patients,
and advanced treatment strategies in animal studies in order
to understand the mechanism of SCI treatment and to ﬁnd
future appropriate clinical applications.
2. Time Courseof Patients withSCI
Time sequence of SCI is divided into three stages: acute
(seconds to minutes after SCI), subacute (minutes to
weeks after SCI), and chronic (months to years after SCI).2 Journal of Tissue Engineering
Thetherapeutictargetshouldbesetaccordingtothesestages.
In the acute and subacute stages, the purpose of treatment is
neuroprotection whereas neural restoration is the target of
chronic stage.
2.1. Primary Injury (Acute Stage). Primary injury is due to
the direct compression and contusion of the spinal cord
due to bone or disc displacement within the spinal column,
as results of fracture-dislocation or burst fracture of the
spine [3]. The injured nerve cells usually fail to restore
normal neural function and progress to spinal shock, which
represents a generalized failure of circuitry in the spinal
neural network, about 24 hours after injury [2]. Primary
injury usually leads to secondary degenerative processes that
further exacerbate SCI.
2.2. Secondary Injury (Subacute Stage). Secondary injury
starts with depolarization and voltage-dependent sodium,
potassium, and calcium ions channel opening. Following
this, calcium ion overload initiates mitochondrial dysfunc-
tion and the activation of cytoplasmic nitric oxide synthase
and phospholipase A2, which leads to microvascular damage
and consequential ischemia, as well as calpain activation
which further leads to axonal damage [4].
2.3. Chronic Stage. After secondary injury, a dense glial scar
accumulates around the lesion of the spinal cord by reactive
astrocytes, glial progenitors, microglia and macrophages,
ﬁbroblasts, and Schwann cells. A cyst usually develops after
contusion SCI, and axons near a cyst can regenerate into
trabeculae,butmostofthespontaneousregenerationprocess
is incomplete [5].
2.4. Treatment Targets to Regenerate Damaged Neural Net-
works in the Spinal Cord. There are four targets to overcome
forthefundamentaltreatmentofadamagedspinalcord.The
ﬁrst target for treatment is the reduction of secondary injury,
such as inﬂammation, edema, and scar formation, all of
whichinterfereinneuronalregeneration.Thenexttreatment
should focus on the regeneration of damaged axons and
myelin. Third target is the reconnection of eﬀerent and
aﬀerent pathways crossing injured axons located in the white
matter of spinal cords which is essential for the restoration of
motor and sensory functions. The last target for treatment is
the injured neurons in the gray matter of spinal cord should
be regenerated for the restoration of function in situ. Most
therapeutic interventions are eﬀective in acute to subacute
stages because the dense scar which would form otherwise
could not be easily removed, and degenerated neuronal and
glial cells are hard to restore once they have reached the
chronic stage.
3.ClinicalAdvancesinSCI
Thus far, there is no treatment of SCI, but several clinical
trials have provided some information on both the regen-
eration of injured neuronal cells and the protection from
additional damage to the remaining neuronal cells. Present
treatmentoption forhumans isonlypharmacological,which
is an expanding potential as there are some new drugs and
cells in ongoing clinical trials.
3.1. Pharmacological Approaches
3.1.1. Steroid Therapy. Methylprednisolone sodium succi-
nate (MPSS) has been investigated in clinical settings and
is known to be eﬀective for improving motor and sensory
functions and reducing the amount of cellular damage from
secondary injury, if it is applied within 8 hours after SCI [6–
8]. MPSS has potencies of antiapoptotic eﬀect on oligoden-
drocytes[9,10]aswellasanti-inﬂammatoryandantioxidant
eﬀects [11, 12] after SCI. But according to the recent studies,
MPSS also brings with it many detrimental eﬀects, such
as the risk for infections and gastrointestinal complications
[13, 14] and insuﬃcient evidence for standard treatment in
patients with acute SCI [14, 15]. MPSS treatment is still only
as an optional choice for acute SCI patients [16, 17].
3.1.2. Monosialotetrahexosylganglioside (GM-1 Ganglioside).
GM-1 ganglioside is naturally located in the outer mem-
branes of nervous tissue and it has been tested in large
scale clinical studies for SCI patients. Some researchers
have revealed that administration of GM-1 ganglioside
could improve the lower extremity, bladder and bowel
function, sacral sensation, and anal contraction even in
severe incomplete SCI (ASIA Impairment Scale B) patients
[18, 19]. Nevertheless no evidence has supported the use
of ganglioside in patients with acute SCI when considering
its eﬀect on the reduction of the death rate and improving
recovery or quality of life in survivors [20].
3.1.3. Cethrin (Rho Pathway Antagonists). Cethrin is a Rho
antagonist which causes downregulation of growth inhibitor
production, but Rho antagonist reportedly block intra-
cellular signaling pathways such as Rho-associated kinase
(ROCK) which is essential for vascular endothelial growth
factor-mediated angiogenesis [21]. In animal study, Rho
antagonist could restore an abnormal increment of Rho in
neurons and glial cells and rapid locomotor improvement
after acute SCI [22]. A phase I/IIa clinical trial revealed that
topical administration of Cethrin was safe following surgical
decompression for patients with SCI [23].
3.1.4. Riluzole (Sodium Channel Blocker). Riluzole is a ben-
zothiazole anticonvulsant sodium channel antagonist which
has neuroprotective eﬀect and promotes functional recovery
after spinal cord contusion of rats [24]. Recently, one
2-year clinical trial for acute SCI patients was approved by
the Food and Drug Administration. The study for patients
with multiple sclerosis in the brain and spinal cord revealed
that Riluzole reduced the rate of cervical cord atrophy, but
with no evidence for clinical improvement [25].
3.1.5.Minocycline. Minocyclineisasecond-generationtetra-
cycline derivate, and it has some neuroprotective eﬀects,
such as inhibition of microglial activation, attenuationJournal of Tissue Engineering 3
of apoptosis, and suppression of free-radical production
through blocking mitochondrial cytochrome c release and
lastly an improved functional recovery in animal SCI [26–
28]. No beneﬁcial eﬀect of Minocycline on animal SCI
models was also reported recently [29] and no clinical trial
for SCI patients was performed.
3.1.6. Erythropoietin. Erythropoietin is located at high con-
centration within capillaries of adult human spinal cords.
It is known to be neuroprotective to ischemia of animal
spinal cord as well as for its hematopoietic eﬀects [30].
Phase II clinical trial showed that the administration of
human recombinant erythropoietin intravenously was rela-
tively safe and seemed to be eﬀective in reducing the infarct
size in stroke patients [31].
3.1.7. Nimodipine. Nimodipine is a calcium channel blocker
and eﬀective to increase cerebral blood ﬂow and restore
behavioral and histopathological abnormalities following
ischemia reperfusion brain injury in rats [32]. Electro-
physiological abnormality was improved after intravenous
administration of nimodipine to the rats with partially
transected spinal cord [33]. One clinical trial was performed
but showed that no diﬀerence was found among SCI patients
receiving nimodipine, MPSS, both of them, and placebo in
acute phase [34].
3.2. Cell Therapy (Table 1). Clinical trial of stem cell trans-
plantation in patients with SCI was reported in 2006 at ﬁrst
[35], and several clinical research projects were performed
to detect the safety and eﬃcacy of transplanted cells to
the patients in SCI (Table 1). Most of these experiments
used autologous bone marrow stromal cells; the results
were relatively safe but the eﬀect was limited. Olfactory
ensheathing cells, Schwann cells, and macrophages were also
attempted to be transplanted to SCI patients. The purpose
of these clinical trials was basically to test safety rather
than therapeutic improvement. Moreover, these studies have
many statistical problems; the sample size of most previous
clinical studies was quite small, they were not double-
blind randomized and had no placebo controls to compare
with which is essential for valid SCI clinical trial [49], and
they introduced unclear mechanisms which might lead to
functional improvements, thus ultimately requiring further
clinical trials.
3.2.1. Bone Marrow Stromal Cells (BMSCs). Mesenchymal
stem cells (MSCs) can be safely and easily obtained from
bone marrow in human for use of autologous transplan-
tation, without any ethical problems. This is very advanta-
geous for clinical application. MSCs secrete cytokines and
neurotrophic factors and also have anti-inﬂammatory eﬀects
[50]. Nine studies were performed using autologous BMSCs
transplantation into SCI patients from 2006, where the total
number of patients was 460. All clinical trials using BMSCs
transplantation were performed outside of United States:
Brazil [35, 43], India [39, 40], Argentina [36], Czech [38],
Russia [41], Turkey [42], and South Korea [37].
Callera and Nascimento ﬁrst reported BMSCs transplan-
tation in 10 SCI patients intrathecally, and they did not
ﬁnd any transplanted cells in cerebrospinal ﬂuid 7 days after
transplantation (Table 1)[ 35]. Moviglia et al. transplanted
autologous bone marrow-driven transdiﬀerentiated neural
stem cells and patient’s autoimmune T cells into the injured
spinal cord, via a feeding artery, in two chronic patients with
spinal cord injury, and they found clear clinical improve-
ments were seen during the 3 months after transplantation,
without any adverse eﬀect [36]. Yoon et al. reported 35
patients with complete SCI who were transplanted with
autologous BMSCs around injured spinal cord in acute,
subacute, or chronic stages, and they found that 20% of
patientssuﬀeredfromneuropathicpainaftertransplantation
but the number of aﬀected cases was not signiﬁcantly
more than controls (7.7%). Less than half (30.4%) of
patients who were transplanted in acute and subacute stages
showed improvements in the ASIA (American Spinal Injury
Association) impairment scale (AIS) during the 10-month
followup period [37]. Functional status in the acute stage
would not be accurate when the patients are in the spinal
shock stage; during several days of the spinal shock stage
just after SCI the sensory and motor functions are usually
disabled even in case of incomplete injury. Therefore, we
cannot be convinced of the transplantation eﬀects on acute-
stage SCI patients. Sykova et al. also found that one of the
12 chronic patients with complete spinal cord injury, as
well as 5 of 8 subacute patients showed sensory and motor
improvements after transplantation of autologous BMSCs
intravenously or intra-arterialy, and they recommended the
therapeutic window of 3 to 4 weeks following injury as
being critical for stem-cell treatment [38]. Pal et al. reported
30 patients with subacute or chronic SCI who received
autologous BMSCs intrathecally, and only incomplete SCI
patients (16.7%) were seen to have improved functionally
without neurological or electrophysiological improvements
[39]. Kumar et al. performed a large-scale clinical trial in
India, consisting of was 297 patients with chronic SCI,
whoweretransplantedwithautologousBMSCsintrathecally,
but detailed information about the period from injury to
transplantation was not clariﬁed and a 3-month followup
period is too short to conclude the results [40]. Chernykh
et al. in Russia and Deda et al. in Brazil transplanted
autologous BMSCs to patients with chronic SCI directly into
the lesion and intravenously [41, 42] or direct injection,
intravenously and intrathecally [42] at the same time, and
they found neurological improvements in many of the
transplanted patients (66.7% and 100% resp.) [41, 42].
Critante et al. in Brazil also reported electrophysiological
improvement in about 66.7% of chronic SCI patients with
paraplegia or tetraplegia at the 30-month followup after
BMSCs transplantation intraarterialy [43].
MSCs are thought to act as a neuroprotector by secreting
various neurotrophic factors, namely: BDNF, NGF, VEGF,
and HGF, rather than by neural regeneration from transd-
iﬀerentiation into neuronal or glial cells [51, 52]. The exact
mechanism of this action is still unknown [53]. Some in
vitro and in vivo studies showed the transdiﬀerentiation of
MSCs into neuron and glial cells [54–57], but the proportion4 Journal of Tissue Engineering
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to neuronal diﬀerentiation was very small and the function
of transdiﬀerentiated cells as neurons is still doubtful [58].
Therefore, neural stem cells or pluripotent stem cells are
appropriate to promote neural restoration or in the replace-
ment of damaged host neurons and glial cells, more than are
MSCs.
3.2.2. Olfactory Ensheathing Cells (OECs). OECs are glial
cells that ensheath the olfactory nerve fascicles and continue
to support regeneration of olfactory axons throughout life in
mammals [59]. Transplanted OECs into injured spinal cord
promote axonal regeneration and functional recovery after
S C Ii na n i m a l s[ 59]. OECs can be obtained via biopsy of the
olfactory mucosa [44].
Mackay-Sim et al. observed six patients with chronic
spinal cord injury for 3 years after transplantation of
autologous OECs directly into the injured spinal cord (Phase
I/IIa design) [44]. All patients were safe, and there were
no signiﬁcant functional changes or neuropathic pain 3
years after transplantation and one patient showed sensory
improvement below the the lesion. Lima et al. found
some neurological, functional, electrophysiological and uro-
dynamic improvements in 20 chronic SCI patients after
OECs transplantation into the injured spinal cord [45]. But
Chhabraetal.reportedsyrinxformationandthelengthening
of myelomalacia seen on MRI after OECs transplantation
in some of the ﬁve chronic SCI patients, without any
neurological or functional improvements [46].
Huang et al. reported clinical trials of OECs transplan-
tation for chronic SCI patients three times to one Chinese
journal and they found some functional improvements
without signiﬁcant complication [60–62]. But Dobkin et
al. reported that among seven chronic SCI patients who
received OECs transplantation from Dr. Huang in China,
ﬁve patients had complications including meningitis and
clinical improvement was neither clear nor proven and the
procedures did not meet international standards of clinical
trials for safety or eﬃcacy [63].
3.2.3. Schwann Cells (SCs). SCs are the supporting cells
surrounding peripheral nerves and form the myelin sheath.
SCs were the ﬁrst transplanted cells into injured spinal
cord in animals [64], and they enhance remyelination of
demyelinated axons and promote axonal regeneration in
combination with polymer scaﬀolds through many animal
studies [53]. In a clinical trial, Saberi et al. transplanted
autologous SCs into the injured spinal cords of 4 patients
with chronic SCI, but only one patient with incomplete
SCI showed sensory and motor improvement 1 year after
transplantation [47].
3.2.4. Macrophages. Peripheral macrophages can synthesize
nerve growth factor after peripheral nerve damage and elim-
inate myelin which inhibits neural regrowth [65]. A phase
I study was performed: incubated autologous macrophages
were transplanted into patients’ spinal cord within 14 days of
injury, and 3 of 8 patients showed improvements of motor
and sensory functions without any critical complications
[48].
4.ExperimentalAdvances inSCI
(through InVivoandInVitroStudies)
4.1. Considering Animal Models and Injury Severity for SCI
Experiments. The contusion model is the most relevant
type for human SCI [66] and appropriate for assessment
of acute management strategies [67]. Computer-assisted
devices using an impactor such as NYU impactor are the
representative tools to regulate the severity of contusion
injury and they can simulate human SCI, but it is hard to
diﬀerentiate the axonal regeneration from the trophic eﬀects
onthefunctionalimprovementfollowingtreatment,because
thesparedaxonsandregeneratingaxonsintheinjuredspinal
cord are not easy to distinguish.
Transection model is more appropriate for studies focus-
ing on axonal regeneration. A gap following transection
can also be made to implant a device or biopolymer
scaﬀolds. Partial transection models, such as the hemisection
or dorsal transection, have generally been used for the
transplantation of neurotrophic factor-containing hydrogel
[68, 69], genetically modiﬁed cells secreting neurotrophic
factors [51]o rb i o p o l y m e rs c a ﬀolds [70, 71]. The complete
transection model is preferred to eliminate the plasticity
of remaining host neurons in the injured spinal cord and
is appropriate for the study of the recovery of autonomic
dysfunctions, such as neurogenic bladder, but the researcher
should consider that this model is the most severe type
of injury and is hard to regenerate, even after appropriate
treatments.
Functional assessment is essential to conﬁrm the treat-
ment eﬀects clinically whether an experiment attempting
neuroprotection orneuronalregenerationis successful.Most
studies using rodent models measure Basso, Beattie, and
Bresnahan (BBB) score as a locomotor function of hindlimb,
and the most meaningful BBB score is 9 (plantar weight-
support) or more compared with nonachieved (below 9)
controls [66]. But in a case of complete transection model,
an increment of BBB score is very limited and the locomotor
function cannot reach to plantar weight support even after
successful treatment. Therefore, other methods such as
tracing of spinal tracts or electrophysiology should be added
to reveal the reconnection of proximal and distal stumps
following spinal cord transection.
4.2. Treatment Focus in SCI. Time sequence of SCI is divided
into three stages as mentioned earlier: acute, subacute, and
chronic, and the treatment strategies diﬀer according to the
stages. Treatments in acute and subacute stages after SCI
should focus on the neuroprotection, and treatment options
in the chronic stage focus on neurorestoration [50].
Treatments for neuroprotection should ideally be started
within several hours of injury to prevent secondary injury
process. Both anti-inﬂammatory drugs and some neu-
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(BDNF) and neurotrophin-3 (NT-3) are known to be eﬀec-
tive in vivo studies. Cell transplantation is not appropriate
in the acute inﬂammatory stage because various cytokines
followinginﬂammation decreasethe survivaloftransplanted
cells and change the properties of diﬀerentiation of trans-
planted stem cells [72, 73]. Biomaterials such as poly
(epsilon-caprolactone) (PLC) and poly (lactic-co-glycolic
acid) (PLGA) have a potency to reduce the inﬂammatory
process and concomitant scar formation in the traumatic
braininjurymodel[74].Also,functionalimprovementswere
seenafterthecell-seededbiopolymerwasimplantedjustafter
spinal cord transection [75, 76].
Neurorestoration strategies are very important in the
clinical setting because most populations of SCI patients
are in the chronic stage. Neurorestoration is divided into
two categories: restoration of host neurons and neural
replacement. The method for the restoration of host neurons
includes suppression of inhibiting factors (which inhibit
to regrowth of host axons) [77, 78], neurotrophic factors
for neurite outgrowth and synaptic plasticity [5], and
transplantation of glial cells for remyelination of host
axons [79]. Pluripotent or multipotent stem cells such as
embryonic stem cells, induced pluripotent stem cells, and
neural stem cells can be sources of exogenous neurons
and glial cells for neural and glial replacement, but the
safety and eﬃciency for human use has not yet been
addressed.
4.3. Stem Cell Therapy. Most of past and current researches
using cell transplantation have been successful in subacute
SCI, but researchers should consider the adverse eﬀects of
stem cells such as tumor formation or abnormal circuit
formation within the injured spinal cord which leads to
abnormal function [80]. Stem cells also can be used as
vehicles for neurotrophic factors and gene delivery as well
as diﬀerentiated neurons and glial cells to promote recovery
[81].
4.3.1. Embryonic Stem Cells. Embryonic stem cells are
pluripotent, being able to diﬀerentiate into speciﬁc cell
lineages of the adult organism, and have an ability to
proliferate in long-term cultures while maintaining their
pluripotent nature [82]. Some researchers have reported the
possibility of chromosomal abnormalities during prolonged
culture [83], teratoma formation due to the remaining
undiﬀerentiated embryonic stem cells within the graft site,
and graft rejection after allogeneic embryonic stem cell
transplantation [82]. Many countries restrict clinical trials
using embryonic stem cells due to ethical and political issues
[84]. Geron Corporation (Menlo park, CA) started the ﬁrst
clinical trials (phase I) of human embryonic stem cells to SCI
patients approved by US Food and Drug Administration last
year [85].
4.3.2. Neural Stem Cells. Neural stem cells (NSCs) can
diﬀerentiate into neurons and glial cells with the support of
neurotrophic factors in vitro. These cells accelerate restora-
tion of host neurons and remyelination of demyelinated
a x o n sa sw e l la sn e u r o n a lc e l lr e p l a c e m e n t[ 81]. Endogenous
NSCs are located in the subventricular zone of the lateral
ventricle and the subgranular zone of the hippocampal
dentate gyrus in the adult human brain, but the self-
renewal capacity following brain or spinal cord injury
is not enough to promote recovery of injury [86]. The
sources of exogenous NSCs are various, from embryonic
stem cells to fetal and adult brain and spinal cord. Some
in vivo studies were performed using NSCs and achieved
functional recovery following SCI [87–89]. Most sources
of NSCs are exogenous; therefore, allograft or xenograft
may cause graft rejection, as in ESCs. Expression of various
neurotrophic factors from diﬀerentiated astrocytes can cause
complications such as allodynia after NSCs transplantation
[90]. Ethical concerns, safety, and eﬃciency should also be
considered for clinical trials [53]. No clinical trials of NSCs
transplantation in SCI patients have been reported until
now.
4.3.3. Induced Pluripotent Stem Cells. Induced pluripotent
stem cells (iPSCs) were ﬁrst introduced in 2006 by Takahashi
and Yamanaka from gene modiﬁed mouse embryonic and
adult ﬁbroblasts [91]. iPSCs have pluripotency, a character-
istic similar to that of ESCs. The transplantation of iPSCs
in human SCI patients can overcome graft rejection after
transplantation with the same potency as ESCs and ethical
and political problems regarding the use of human embryos
[92].
Recently, some investigators use iPSCs to restore
impaired functions after focal cerebral ischemia in rats was
combined with ﬁbrin glue. They found functional improve-
ment and anti-inﬂammatory response following transplan-
tation [93]. Undiﬀerentiated iPSCs have tumerigenesis sim-
ilar to ESCs. Kawai et al. reported a tridermal teratoma
after transplantation of iPSCs into the ischemic brain in
mice [94]. Viral integration due to the use of viral vectors
during the reprogramming process, c-Myc which is one
of four transcription factors has oncogenic properties, and
incomplete reprogramming due to the slow and relatively
ineﬃcient process are other problems which need to be
solved before clinical application [95].
The techniques and methods to generate iPSCs continue
to be developed rapidly. Recombinant proteins or small
moleculesalsocanbeusedforgeneratingiPSCs[96,97].Kaji
e ta l .m a d ei P S C sw i t h o u tv i r a lv e c t o r si nm o u s ea n dh u m a n
ﬁbroblasts, eliminating exogenous transcriptions factors
with high eﬃciency [98]. The combination of transcription
factors excluding c-Myc and even two of them were enough
to regenerate iPSCs by some researchers [97, 99]. More
eﬃcient reprogramming was possible using human amnion-
derived cells and three transcription factors [100]. We hope
for a novel method to generate iPSCs which diﬀerentiate into
neurons and glial cells eﬀectively and safely, for use in SCI
patients in the near future.
4.4. Neurotrophic Factors. Neurotrophic factors (NTFs) are
known to modulate neuronal survival, axonal outgrowth
and synaptic reformation after SCI [5]. NTFs which have8 Journal of Tissue Engineering
therapeutic eﬀects on the regeneration following SCI are
brain-derived neurotrophic factor (BDNF) [51], Neuro-
trophin-3 (NT-3) [101], glial derived neurotrophic factor
(GDNF) [102], nerve growth factor (NGF) [103], ﬁbroblast
growth factor (FGF) [104], insulin-like growth factor (IGF)
[103], ciliary neurotrophic factor (CNTF) [105], and inosine
[106].
Recent studies using NTFs and nonviral vector delivery
systems are shown in Table 2. Sasaki et al. applied BDNF-
secreting human MSCs into the dorsal-transected spinal
cord in rats, and they found functional improvement and
increments of ﬁber sprouting in the corticospinal tracts [51].
Han et al. used collagen-binding BDNF to hemisected spinal
cords in rats, and they also reported functional improvement
[68]. NT-3 could be delivered through genetically modiﬁed
OECs or a heparin delivery system. Functional improvement
and increment of neural ﬁber density were achieved fol-
lowing transplantation [69, 101]. GDNF-secreting MSCs or
cotransplantation with SCs could increase GDNF secretion
and regenerated axons and blood vessels [102, 107]. CNTF-
secreting oligodendrocyte precursor cells were well survived
and promoted remyelination of demyelinated axons and
functional improvement after transplantation into contused
spinal cord of rats [105].
4.5. Suppression of Inhibiting Factors. Inhibiting factors
which interfere the recovery of damaged axons and
their reconnection after trauma to central nervous system
are chondroitin sulfate proteoglycans (CSPG) [108, 109],
myelin-associated glycoprotein (MAG) [110], Nogo-A [111]
and oligodendrocyte-myelin glycoprotein (OMgp) [112].
Their mechanisms and functions are well understood in
vitro studies, and some animal studies were performed
for applying the suppressor of these inhibiting factors.
Chondroitinase ABC (chABC), which digests CSPG, was
administered intrathecally into injured spinal cord in rats,
and this treatment upregulated regeneration-associated pro-
tein, restored electrophysiological activities, and promoted
functional recovery [113]. Ikegama et al. performed chABC
treatment combined with NSCs transplantation to the con-
tused spinal cord of rats, and chABC-treated MSCs were well
migrated and enhanced the outgrowth of growth associated
protein-43 positive axons [109]. A recent in vivo study, how-
ever, failed to show improved functions following chABC
injection into hemisected cervical cords of rats [108]. As in
NTFs, suppressors of inhibiting factors should be released
by genetically modiﬁed cells or combined with polymer-
delivery system, to gain sustained eﬀects and concomitant
functional improvement following SCI. Administration of
Nogo-66 receptor, which blocks MAG, Nogo, and OMgp, via
osmotic pump improved electrophysiologic and locomotor
recovery after dorsal transection of thoracic spinal cord
in rats [114], and immunization with Nogo-66 receptor
also showed axonal regeneration and locomotor recovery
after dorsal hemisection and spinal cord contusion in rats
[115]. Sialidase, an inhibitor of MAG was eﬀective on axonal
sprouting and locomotor function in spinal cord contusion
model in rats [116].
4.6. Biomaterials. Development of biomaterials that are
bioactive, compatible with nerve cells, and even nerve regen-
erative is also considered as a potential tool. In particular,
the biomaterials can be an eﬀective carrier of drugs and
n e u r o t r o p h i cf a c t o r sa sw e l la sp l a yas c a ﬀolding role of stem
cells. When drug or NTF was loaded in a polymer nanocar-
rier, the drug delivery systems better reduce inﬂammation in
acute stage [117] and act as a guidance of outgrowing axons
or synaptic reconnection in subacute and chronic stages
[118] .S o m eb i o p o l y m e r ss u c ha sP L G Aa n dP L At h e r eh a v e
also been reported to have anti-inﬂammatory capacity [119].
Even better is the engineering of the biomaterials to have
microchannels or in the form of ﬁbers in terms of improving
a directionality of regenerating axons after SCI [120, 121].
Biomaterial-based treatment has some disadvantages; long-
term implantation of nonbiodegradable tube type scaﬀold
causes chronic compression of regenerating axons [122], and
the transplant site can act as a sink, attracting sprouting
axons but not allowing them to escape and reconnect with
the host spinal cord.
4.6.1. Delivery Systems. To enhance the eﬃcacy of neu-
rotrophic factors and inhibiting agents, the use of an
appropriate carrier can be considered. A range of polymeric
materials (natural or synthetic origin) have been developed
for targeting either systematic or local delivery of drugs.
While liposome, micelles and dendrimers are usually used
for the systemic delivery into the central nervous sys-
tem, degradable polymers such as poly(lactic acid) (PLA),
poly(lactic-co-glycolic acid) (PLGA), chitosan, and collagen
arenewlydevelopedforthelocaldeliveryofdrugs[123,124].
Compared to the systematic delivery, local delivery system
has many advantages in the SCI applications. Neurotrophic
factors, suppressor of inhibiting factors can be delivered
into injured spinal cord without any systemic side eﬀects,
and sustained release of regenerating factors is possible
avoiding the diﬃculty in penetration into the blood-brain
barrier. Degradable polymer-based delivery systems enable
thecontrolofdrugdosageandreleaserateafterimplantation
and modulation of the biodegradation rate after therapeutic
period. Some recent studies have demonstrated the eﬃcacy
of degradable polymeric materials such as ﬁbrin or PLGA
fordeliveringneurotrophicfactor[125,126],andcollagenor
heparin-binding system for delivering neurotrophic factors
into the injured spinal cord in animals [68, 69]. Hydrogel
system made of hyaluronan and methylcellulose was also
shown to deliver eﬀectively erythropoietin intrathecally as
the cavitation after SCI was greatly reduced [127].
Nanoparticulate carriers such as nanospheres and
nanocapsules are good candidate for delivering proteins and
even genes. A range of polymers have been developed in
the form of nanospheres and nanocapsules and the sizes
could be tunable to tens to a few hundreds of nanometers.
As the compositions are degradable and the degradability
is adjustable, the drug release rate can also be eﬀectively
modulated [105]. Drugs can be encapsulated either within
the polymer nanoparticulates during the processing stage
or posttreated (conjugated) on the surface of the particlesJournal of Tissue Engineering 9
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through chemical reactions. Furthermore, the nanoparticu-
lates can be combined with 3D tissue scaﬀolds to provide
a sustained release system of single or multiple drugs for
potential regeneration of nerve tissues. Synthetic polymer
PLGA microspheres embedded with neurotrophic factors
have been the most widely studied either with or without the
combination of a variety of polymeric scaﬀolds. Wang et al.
performed local administration of PLGA with glial cell line
derived neurotropic factor (GDNF) and reported eﬀective
preservation of neuronal ﬁbers leading to the hindlimb
locomotor recovery in rats with SCI [128]. Takenaga et al.
has demonstrated the prostaglandin E1 loaded nanoparticles
are eﬀective on locomotor recovery and decrement of cavity
volume after spinal cord contusion in rats [129]. Moreover,
Das et al. applied quercetin-loaded nanoparticles into the
brain lesion model and achieved antioxidative eﬀect [130].
While there have been increasing reports on the in vitro
performance of the delivery systems, there are still limited
animal studies using the nanocarriers for the treatment of
SCI.
4.6.2. Scaﬀolds. Biomaterials can be developed to support
and guide cell behaviors by engineering the macro- and
micromorphology. To play an eﬀective role as a scaﬀold,
tissueperfusionofthebiomaterialsisprerequisite.Therefore,
hydrogels or porous structured materials are the general
form of scaﬀolds as these can provide large space for cells
to grow and migrate and the continuous supply of ﬂuid
and nutrients. When scaﬀolds are implanted in lesions
of CNS they can be a supporting matrix of surrounding
cells to adhere and migrate to gain regenerative potential.
In this stage, the properties of scaﬀolds, such as surface
status, chemical composition and physical stiﬀness are
the possible determinants of the cell behaviors and fate.
In other words, one needs to consider signiﬁcantly the
design of scaﬀolds in terms of physical and chemical
properties to gain optimal recovery and regeneration of
nerve tissues. In practical issues, method for implantation
of scaﬀolds into injured spinal cord should be considered
because most human spinal cord injuries involve con-
tusions of the spinal cord. To minimize adjacent tissue
damage during implantation, injectable type biopolymer is
preferred.
Among the compositions, degradable polymers, such
as PLA and PLGA and natural collagen have been most
popularly used as the porous scaﬀolds for the treatment
of SCI. The PLA porous scaﬀolds were fabricated to have
longitudinally aligned pores with incorporation of BDNF
and implanted in the transected thoracic spinal, which,
however, showed little improvement in the axon numbers
along the scaﬀold [133]. When the same scaﬀold was seeded
with genetically modiﬁed Schwann cells which secrete a
bi-functional neurotrophin (D15A) with BDNF and NT-
3 activities and implanted for 6 weeks, modest axonal
regeneration was noticed [134]. In another study of PLGA,
when human NSCs were seeded into the porous scaﬀold
and then implanted into hemisected spinal cord of monkey,
therewasnosigniﬁcantfunctionalimprovement[75],which,
however, was reported to be more suitable for the brain
repair applications [124].
Fortheinvivostudy,thosepolymericscaﬀoldsneedtobe
developed into a tubular form, which support axonal guid-
ance of nerve tissues after SCI, and the examples of tubular
form scaﬀolds are summarized in Table 3. The incorporation
of neurotrophic factors within the tubular guidance made
of synthetic hydrogel (pHEMA-MMA) or ﬁbrin has shown
an improvement of speciﬁc supraspinal and local axonal
regeneration and locomotor function after complete spinal
cord transection [131]. When NSCs or SCs were seeded
within the PLGA scaﬀold containing seven small channels
inside,lesion-crossingneuronsandoutgrowingaxonswithin
scaﬀold were increased however, there was no functional
improvement [76, 132]. Nomura et al. made chitosan tube
and implanted with NSCs into completely transected spinal
cord of rats, but no functional improvement was still noticed
[120].
Aﬁ b r o u sf o r mo fs c a ﬀolds, such as microﬁbers and
nanoﬁbers, has also been developed as a nerve guiding
scaﬀold after aligning or texturing the morphology to
enhance the neurite outgrowth and cell guidance. Some
in vitro studies showed the neurite outgrowth along the
aligned ﬁbers [135–137]. However, there were few in vivo
reports on the ﬁbrous scaﬀolds. One of the challenges
in the ﬁbrous scaﬀolds is that this structure is hard to
directly apply to animal models, therefore, new techniques
are needed to develop them into three dimensional scaﬀolds
for the SCI implantation. Currently, there is increasing trend
of researches from using only the scaﬀolds in tubular or
ﬁbrous form towards their applications in combining either
neurotrophic delivery systems and/or cells.
4.7. Rehabilitation: Exercise Eﬀects. Since several decades
ago, exercises such as locomotor training, strengthening
and passive range of motion exercises, and occupational
therapies have been commonly performed on SCI patients
in rehabilitation units. Various types of exercises and sup-
porting strategies including functional electrical stimulation
and robot-assistive devices have been developed to enhance
walking capacity for SCI patients, but the eﬀects on the
regeneration of injured spinal cord according to the types of
exercise remain unknown [138].
The cellular and molecular mechanisms of the eﬀect of
exercise training after SCI are not clearly understood. Some
researchers have recently tried to reveal theses mechanisms
through animal studies. Endogenous NSCs exist around
the central canal of the adult spinal cord, and Foret et
al. found that treadmill exercise for compressive SCI rats
enhanced locomotor recovery and increased the number of
NSC proliferation [139]. The supraspinal pathway, including
the somatosensory cortex, might be changed after SCI. Kao
et al. made a complete transection model of neonatal rats
and found that treadmill exercise for 6–8 months could
restore the reduced response of the somatosensory cortex
to forelimb stimulation, and the percent and magnitude of
responding cells in the hindlimb somatosensory cortex was
increased after exercise [140]. BDNF level in the spinal cordJournal of Tissue Engineering 11
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increases following 4-weeks of treadmill exercise in normal
adult rats [141], and selective upregulation of BDNF in the
motor nuclei improves functional recovery in complete SCI
rats[142].But earlyexercisein theacuteinﬂammatory phase
(1 week) after contused SCI in rats can induce allodynia
with aberrant sprouting of C aﬀerent ﬁbers through BDNF-
tropomyosin-related kinase B signaling [143]. Maier et al.
performed combination therapy with anti-Nogo-A antibody
and treadmill exercise to incomplete SCI rats, but this
combination did not show synergistic eﬀects, due to the
diﬀerential mechanisms between two modalities [144].
4.8. Combinations of Therapeutic Strategies. Combination
therapies are expected to enhance the regeneration after
SCI because each therapeutic strategy targets a diﬀerent
mechanism and result. For example, the combination of
strategies which aﬀect diﬀerent stages, neuroprotection and
neurorestoration, will improve the injured spinal cord more
than a single strategy [145]. But the mechanisms of many
therapeutic strategies are still unknown; therefore, combi-
nations of single useful therapeutic strategies do not always
show synergistic result.
Bunge found that the combination of SCs, OECs, and
chABC application to spinal cord transection and the bridge
model of rats in the acute stage could improve locomotor
function and increase myelinated axons in the transected
spinal cord. As well, it was found that the combination of
SCs and cyclic AMP application in the subacute stage after
contusion SCI of rats was the best way to improve locomotor
function and increase serotonergic nerve ﬁbers [145]. In
Table 4, we reviewed current in vivo studies on combination
t h e r a p i e sf o rS C Ir e p a i r .
4.8.1. Cotransplantation of Stem Cells and OECs. Wang et al.
cotransplanted NSCs and OECs into the partially transected
spinal cords of rats 7 days after injury, and found functional
improvement was signiﬁcant in the cotransplanted group
[146]. However Amemori et al. could not reveal signiﬁcant
functional improvement in the group of cotransplantation
of MSCs and OECs into contused spinal cords in rats [147].
4.8.2. Combinations of Stem Cells with NTFs or SIFs. Rho
kinase inhibitors, which prevent RhoA activation, were
combined with MSCs and transplanted into compressive
or contused SCI in rats and functional improvement was
better than it was in MSCs or Rho kinase inhibitor
transplantation alone groups [148, 149]. Johnson et al.
performed combination therapy including ﬁbrin scaﬀolds
containing ESC-derived neural precursor cells (NPCs), NT-3
and platelet-derived growth factor (PDGF) with a heparin-
binding delivery system into the dorsal hemisected spinal
cords in rats 2 weeks after injury. They found increment
of NPCs survival and diﬀerentiation into neurons 2 weeks
after transplantation [150]. The combination therapy of
OECs and BDNF into cervical SCI rats, however, reversely
worsened the functional status compared with groups which
received OECs, BDNF, or even the vehicle and failed to
regenerate supraspinal axons through and beyond the lesion
site [151].
4.8.3. Combinations of NTFs with SIFs. The combination
treatment of thermostabilized chABC and NT-3 in a hemi-
section SCI model of rats showed increments of axonal
outgrowth and functional improvement [152]. Sharma tried
to combine some NTFs, including BDNF, GDNF, NGF, and
NT-3, with time intervals for the treatment of transected
spinal cords of rats, and they found that the combination
of BDNF and GDNF at 60 and 90 minutes after injury was
eﬀective in reducing edema formation and cell injury, and
achieved concomitant functional improvement [103].
4.8.4. Combinations of SIFs with Neuroprotective Agents.
Clenbuterol is the β2-adrenoceptor agonist which acts as a
neuroprotective agent inducing expression of neurotrophic
factors and anti-inﬂammatory properties [155]. The com-
bination of chABC and clenbuterol showed the increments
of axonal re-growth, lesion-crossing axons and concomitant
functional improvement in the complete transection model
ofratspinalcords[153].MPSSisastronganti-inﬂammatory
agent, as mentioned earlier, and the Nogo 66 receptor
can bind MAG, Nogo-A and OMgp, which block neurite
outgrowth. The combination of MPSS and Nogo 66 receptor
antagonist and intrathecal administration via osmotic pump
enabled the increment of the survival of neurons and
oligodendrocytes and locomotor improvement [154].
5. Concluding Remarks
Recent clinical trials of stem cell transplantation for SCI
patients were relatively safe and showed functional improve-
ment, to some extent; however, many problems still exist
and need to be considered for stem cells to be used
clinically. Autologous MSCs and OECs that were used in
previous clinical studies are not enough to replace damaged
neuronal cells and to reconnect the impaired spinal tracts
for the fundamental regeneration of injured spinal cord.
Any clinical trials for chronic SCI patients, who constitute
the greatest population of SCI patients at present, did not
show functional improvement. Clinical trials of stem cell
transplantation for the chronic SCI patients still require a
progress to phase II studies. There was no evidence as to
which method of stem cell delivery to use, such that a better
outcome is achieved, and also the amount of transplanted
stem cells was quite variable. Some treatment options are
developed and have advanced recently, including induced
pluripotent stem cells, neurotrophic factors or suppressor of
inhibiting factors, biopolymers and exercise training, but the
mechanismsofeachstrategyarenotclearenoughtoprogress
to clinical translation. The researchers have to reveal the
molecular and cellular mechanism of each therapeutic strat-
egy through animal study, and then combine the strategies
with diﬀerent mechanisms of treatment or diﬀerent stages of
SCI to thereby gain a synergistic eﬀect. Clinical trials would
ideally follow completion of these animal studies. Recent
pioneering researches of regenerative medicine, includingJournal of Tissue Engineering 13
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induced pluripotent stem cells, biopolymer scaﬀolds, and
deliverysystems,areprogressingveryrapidlyandacombina-
tion of them, or else the combination with previous eﬀective
strategies is, in the near future, expected to create a novel
method for the fundamental regeneration of SCI.
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